Late-breaking abstract at #EHA25 Subcutaneous #Daratumumab in Light-chain (AL) Amyloidosis - ANDROMEDA study

- CR 53% for DARA-CyBorD vs 18% for CyBorD
- 6-month cardiac response rate was 42% vs 22%, renal 54% vs 27%

@Genmab $GMAB $JNJ #Darzalex #Faspro

https://t.co/TJf1AgH6Tc